Skip to search formSkip to main contentSkip to account menu

HL156A

National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

GuanidinesPyrrolidines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
AMP-activated protein kinase activator , HL 156 A reduces thioacetamide-induced liver fibrosis in mice and inhibits the activation of cultured hepatic stellate cells and macrophages
Cirrhosis, the end-stage of hepatic fibrosis, is not only life-threatening by itself, but also a causative factor of liver cancer… 
2016
2016
The AMPK activators, HL156A and HL176OUT04 reduce thioacetamide-induced hepatic fibrosis via the inhibition of hepatic stellate cell activation
2015
2015
HL 156 A , a novel AMP-activated protein kinase activator , is protective 3 against peritoneal fibrosis in an in-vivo and in-vitro model of peritoneal 4 fibrosis 5 6
45 HL156A is a novel adenosine5’-monophosphate-activated protein kinase (AMPK) activator. We 46 aimed to investigate the… 
2015
2015
ATPS-39COMBINATORY EFFECT OF A NEWLY DESIGNED BIGUANIDE (HL156A) AND TEMOZOLOMIDE AGAINST GLIOBLASTOMA TUMORSPHERE.
2008
2008
The AMPK activators, HL156A and HL176OUT04 reduce thioacetamide-induced hepatic fibrosis via the inhibition of hepatic stellate cell activation AMPK
.......................................................................1 LIST OF FIGURES… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)